Chairman, CEO and Co-Founder
Frédéric Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011, and as the chairman of our board of directors since May 2016.
Previously, he served as the General Manager, Research of Abbott Laboratories from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, including Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, and at Laboratoires Fournier SA prior to its acquisition by Solvay in 2005. Positions at Laboratoires Fournier included: Vice-President, Strategic Marketing and Vice-President, U.S. Operations. Furthermore, Mr. Cren served as a member of the Executive Committees of both Solvay Pharmaceuticals and Laboratoires Fournier. Before joining the pharmaceutical industry, Mr. Cren was a consultant with The Boston Consulting Group in their healthcare practice for eight years.
Mr. Cren received a master’s degree in business administration from INSEAD, a master’s degree in international relations from Johns Hopkins University and a bachelor’s degree in economics from Paris IX Dauphine University.
Pierre Broqua, Ph.D.
CSO and Co-Founder
Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011, and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016.
Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005.
He holds a Ph.D. in pharmacology from the University of Paris Descartes and a master’s degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris.
Chris Buyse has served as a member of our board of directors since February 2017. Chris Buyse is currently the managing partner of Fund+, which is a life sciences investment fund that he co-founded in 2015.
Previously, Mr. Buyse was Chief Financial Officer at ThromboGenics NV, a public biotechnology company, from 2006 to 2014. He was previously Chief Financial Officer of CropDesign N.V, a Belgian biotechnology company.
Before this, he was Finance Director of WorldCom/MCI Belgium-Luxembourg, a telecommunications company, was Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies N.V., an IT company, and held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent director of Celyad SA, a public biotechnology company, as well as iTeos Therapeutics SA, and Bioxodes SA, each of which are biotechnology companies.
Mr. Buyse holds a master’s degree in applied economic sciences from the University of Antwerp and a master’s degree in business administration from the Vlerick School of Management in Ghent.
Lucy Lu has served as a member of our board of directors since May 2018.
She has been the President and Chief Executive Officer of Avenue Therapeutics, Inc., a public biotechnology company, since its inception in 2015. Previously, she was Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. from 2012 to 2017.
Before working in the biotechnology industry, Dr. Lu worked in healthcare-related equity research and investment banking, including as Senior Biotechnology Analyst at Citigroup Inc. from 2007 to 2012. She currently serves as a board member of Veru Inc., a public biopharmaceutical company.
Dr. Lu holds a doctor of medicine degree from the New York University School of Medicine and a master’s degree in business administration from the Leonard N. Stern School of Business at New York University. She also received a bachelor’s degree from the University of Tennessee’s College of Arts and Science.
Chief Financial Officer of Advanced Accelerator Applications (AAA) from 2003 to 2018, Heinz Maeusli has been instrumental in growing this company into a global leader in its sector. As such, he has driven the listing of AAA on the Nasdaq stock exchange in November 2015 and contributed to AAA’s sale to Novartis in January 2018. Throughout his career, he has developed an expertise in the operational, organizational, financial and cultural complexities of growing and integrating international companies.
Heinz Maeusli holds an MBA from Columbia University, New York, USA and a lic.oec. from the University of
St.Gallen in Switzerland.
With more than 15 years of experience in operational and strategic management within the pharmaceutical industry, Mrs Ouzren has been Chief Executive Officer and Director of Sensorion since 2017. She started her career at Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilars business unit. In 2014, Mrs Ouzren became Vice President of the Global Hemophilia Franchise at Baxalta, which had been incorporated within the Shire group. In 2016, she headed up the Global Genetic Diseases Franchise at Shire, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.
Nawal Ouzren holds a Master’s degree in Chemical Engineering from the Technical University of Berlin, Germany, and a Master of Science in Chemical Engineering from the Université de Technologie de Compiègne, France.
Annick Schwebig has served as a member of our board of directors since February 2017.
In 2000, she founded Actelion Pharmaceuticals France SAS, a pharmaceuticals company specializing in developing drugs for orphan diseases, and was its Chairman and Chief Executive Officer from 2000 to 2015. Ms. Schwebig has held senior positions in the pharmaceutical industry, including Vice President Medical Affairs France and Vice President Research and Development Europe at Bristol-Myers Squibb from 1983 to 2000.
Ms. Schwebig has been a member of the board of directors of Cellectis SA, a biotechnology company, since 2011. Ms. Schwebig is a graduate of the Paris Faculty of Medicine.